Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
featured
Published in Cardiology

Expert Opinion / Commentary · October 09, 2013

The Continuous Saga of Statins

Written by
Eugenia Nikolsky MD, PhD, FACC

 

 Save  Recommend
 Share

Additional Info

  1. Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004; 62(4): 273-8.

  2. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ, Moscucci M. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005; 118(8): 843-9.

  3. Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D'Ambrosio A, Montinaro A, Di Sciascio G. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial. Am J Cardiol. 2011 Jul 1;108(1):1-7.

  4. induced nephropathy] trial. Am J Cardiol. 2011 Jul 1;108(1):1-7. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, Youn TJ, Chung WY, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial--a randomized controlled study. Am Heart J. 2008 Mar;155(3):499.e1-8.

  5. Li Y, Liu Y, Fu L, Mei C, Dai B (2012) Efficacy of Short-Term High-Dose Statin in Preventing Contrast-Induced Nephropathy: A Meta-Analysis of Seven Randomized Controlled Trials. PLoS ONE 7(4): e34450.

  6. Zhang BC, Li WM, Xu YW. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol. 2011 Nov-Dec;27(6):851-8.

  7. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome. Results from Protective effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome (PRATO-ACS Study). J Am Coll Cardiol. 2013.

  8. Han Y, Zhu G, Han L, MD Hou F, Huang W, Liu H, Gan J, Jiang T, Li X, Wang W, Ding S, Jia S, Shen W, Wang D, Sun L, Qiu J, Wang X, Li Y, Deng J, Li J, Xu K, Xu B, Mehran R, Huo Y. Short-Term Rosuvastatin Therapy for Prevention of Contrast-Induced Acute Kidney. Injury in Patients with Diabetes and Chronic Kidney Disease. J Am Coll Cardiol. 2013.

  9. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcysteine in the prevention of Radiocontrast agent- induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15(2):407–410.

  10. Briguori C, Visconti G, Rivera NV, Focaccio A, Golia B, Giannone R, et al. Cystatin C and contrast-induced acute kidney injury. Circulation. 121(19): 2117-22.

  11. McCullough PA, Williams FJ, Stivers DN, Cannon L, Dixon S, Alexander P, Runyan D, David S. Neutrophil gelatinase-associated lipocalin: a novel marker of contrast nephropathy risk. Am J Nephrol. 2012;35(6):509-14.

Further Reading

Most Read This Week

Recently Updated